Toxicities significantly associated with genotypes in a multivariate analysis
| Toxicity, genotype* . | Self-reported race† . | AIMs-determined race‡ . | ||
|---|---|---|---|---|
| Odds ratio (95% confidence limits) . | P . | Odds ratio (95% confidence limits)‡ . | P . | |
| Induction phase | ||||
| Gastrointestinal | ||||
| GSTT1 null vs nonnull | 4.77 (1.4-16.3) | .013 | 5.22 (1.50-18.1) | .009 |
| VDR intron8 GG vs AA or AG | 6.85 (1.73-27.0) | .006 | 6.67 (1.64-25.0) | .008 |
| Infection | ||||
| CYP3A5 GG vs AA or AG | 4.61 (1.11-19.2) | .035 | 5.56 (1.32-25.0) | .019 |
| RFC AA or AG vs GG | 3.25 (1.17-9.07) | .024 | 3.25 (1.16-9.13) | .026 |
| VDR intron8 GG vs AA or AG | 3.14 (1.4-7.09) | .005 | 3.13 (1.39-7.14) | .006 |
| Hyperbilirubinemia | ||||
| GSTM1 null vs nonnull | 1.95 (1.06-3.58) | .032 | 2.00 (1.08-3.69) | .027 |
| UGT1A1 7/7 vs others | 3.05 (1.22-7.64) | .017 | 2.98 (1.19-7.46) | .02 |
| VDR FokI CT or TT vs CC | 1.94 (1.04-3.61) | .036 | 2.00 (1.05-3.70) | .034 |
| VDR intron8 GG vs AA or AG | 1.94 (1.04-3.62) | .037 | 2.00 (1.06-3.85) | .032 |
| Consolidation phase | ||||
| Gastrointestinal | ||||
| RFC AA or AG vs GG | 10.4 (1.35-80.4) | .025 | 10.7 (1.37-82.7) | .024 |
| Hyperbilirubinemia | ||||
| UGT1A1 7/7 vs others | 13.0 (4.1-41.3) | < .001 | 13.4 (4.27-41.9) | < .001 |
| Continuation phase | ||||
| Gastrointestinal | ||||
| RFC AA or AG vs GG | 2.01 (1.06-4.11) | .033 | 2.03 (1.02-4.01) | .042 |
| Hyperbilirubinemia | ||||
| CYP3A5 GG vs AA or AG | 2.67 (1.03-6.94) | .044 | 3.13 (1.16-8.33) | .023 |
| GSTT1 nonnull vs null | 4.18 (1.2-14.7) | .025 | 4.55 (1.22-16.7) | .024 |
| RFC GG vs AA or AG | 2.99 (1.61-5.59) | .001 | 2.70 (1.47-5.0) | .001 |
| TYMS others vs 3/3 | 2.08 (1.01-4.32) | .048 | 2.22 (1.04-4.80) | .038 |
| UGT1A1 7/7 vs others | 17.0 (7.23-39.9) | < .001 | 18.27 (7.82-42.7) | < .001 |
| Peripheral neurotoxicity | ||||
| CYP3A5 AA or AG vs GG | 2.81 (1.24-6.39) | .014 | 2.76 (1.34-5.71) | .006 |
| VDR intron8 AA or AG vs GG | 2.22 (1.06-4.67) | .035 | 2.16 (1.03-4.51) | .042 |
| Central nervous system | ||||
| GSTP1 GG vs AG and AA | 3.32 (1.41-7.81) | .006 | 2.70 (1.18-6.25) | .020 |
| Toxicity, genotype* . | Self-reported race† . | AIMs-determined race‡ . | ||
|---|---|---|---|---|
| Odds ratio (95% confidence limits) . | P . | Odds ratio (95% confidence limits)‡ . | P . | |
| Induction phase | ||||
| Gastrointestinal | ||||
| GSTT1 null vs nonnull | 4.77 (1.4-16.3) | .013 | 5.22 (1.50-18.1) | .009 |
| VDR intron8 GG vs AA or AG | 6.85 (1.73-27.0) | .006 | 6.67 (1.64-25.0) | .008 |
| Infection | ||||
| CYP3A5 GG vs AA or AG | 4.61 (1.11-19.2) | .035 | 5.56 (1.32-25.0) | .019 |
| RFC AA or AG vs GG | 3.25 (1.17-9.07) | .024 | 3.25 (1.16-9.13) | .026 |
| VDR intron8 GG vs AA or AG | 3.14 (1.4-7.09) | .005 | 3.13 (1.39-7.14) | .006 |
| Hyperbilirubinemia | ||||
| GSTM1 null vs nonnull | 1.95 (1.06-3.58) | .032 | 2.00 (1.08-3.69) | .027 |
| UGT1A1 7/7 vs others | 3.05 (1.22-7.64) | .017 | 2.98 (1.19-7.46) | .02 |
| VDR FokI CT or TT vs CC | 1.94 (1.04-3.61) | .036 | 2.00 (1.05-3.70) | .034 |
| VDR intron8 GG vs AA or AG | 1.94 (1.04-3.62) | .037 | 2.00 (1.06-3.85) | .032 |
| Consolidation phase | ||||
| Gastrointestinal | ||||
| RFC AA or AG vs GG | 10.4 (1.35-80.4) | .025 | 10.7 (1.37-82.7) | .024 |
| Hyperbilirubinemia | ||||
| UGT1A1 7/7 vs others | 13.0 (4.1-41.3) | < .001 | 13.4 (4.27-41.9) | < .001 |
| Continuation phase | ||||
| Gastrointestinal | ||||
| RFC AA or AG vs GG | 2.01 (1.06-4.11) | .033 | 2.03 (1.02-4.01) | .042 |
| Hyperbilirubinemia | ||||
| CYP3A5 GG vs AA or AG | 2.67 (1.03-6.94) | .044 | 3.13 (1.16-8.33) | .023 |
| GSTT1 nonnull vs null | 4.18 (1.2-14.7) | .025 | 4.55 (1.22-16.7) | .024 |
| RFC GG vs AA or AG | 2.99 (1.61-5.59) | .001 | 2.70 (1.47-5.0) | .001 |
| TYMS others vs 3/3 | 2.08 (1.01-4.32) | .048 | 2.22 (1.04-4.80) | .038 |
| UGT1A1 7/7 vs others | 17.0 (7.23-39.9) | < .001 | 18.27 (7.82-42.7) | < .001 |
| Peripheral neurotoxicity | ||||
| CYP3A5 AA or AG vs GG | 2.81 (1.24-6.39) | .014 | 2.76 (1.34-5.71) | .006 |
| VDR intron8 AA or AG vs GG | 2.22 (1.06-4.67) | .035 | 2.16 (1.03-4.51) | .042 |
| Central nervous system | ||||
| GSTP1 GG vs AG and AA | 3.32 (1.41-7.81) | .006 | 2.70 (1.18-6.25) | .020 |
First genotype listed had a higher risk of toxicity compared with the second genotype listed.
Odds ratio and P value for genotype predictors of toxicity adjusted for nongenetic predictors of toxicity using self-reported race.
Odds ratio and P value for genotype predictors of toxicity adjusted for nongenetic predictors of toxicity using AIMs-determined race.